NVAX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -14.65. Updated 2026-07-23.
Novavax (NVAX) Research Hub
Novavax (NVAX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 9.42 USD (-4.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.65, market cap 1.31B. This hub links to the full technical, earnings and options research available for NVAX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 9.42 USD (-4.37%) |
| 52-week range | 7.15 USD – 10.75 USD |
| Trend regime | Range |
| 14-day RSI | 68.8 (Bullish) |
| Trailing P/E | -14.65 |
| Market cap | 1.31B |
| Dividend yield | 0.00% |
Available research for NVAX
Covered Call on NVAX: how it works, illustrative setup around the real 9.42 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVAX: how it works, illustrative setup around the real 9.42 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVAX: how it works, illustrative setup around the real 9.42 USD price, max profit/loss, breakeven and when to use it. Educational.
NVAX technical analysis: range, last 9.42 USD, RSI 68.8, 52w range 7.15 USD–10.75 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NVAX in?
Novavax (NVAX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NVAX in an uptrend or downtrend?
As of 2026-09-11, NVAX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVAX's trailing P/E ratio?
NVAX's trailing P/E is -14.65, with a market cap of 1.31B. See the earnings research page for full valuation detail.